USFDAMay 7, 2026, 04:08 PM
NextCure SIM0505 Gets FDA Fast Track; ASCO Data Soon; Q1 Net Loss $9.8M
AI Summary
NextCure announced that its SIM0505 program received FDA Fast Track designation for platinum-resistant ovarian cancer and will present initial Phase 1 data at ASCO 2026 on June 1. The company also initiated dose optimization for SIM0505 in gynecologic cancers and plans to expand trial sites into Canada and Europe. For Q1 2026, NextCure reported a net loss of $9.8 million, an improvement from the $11.0 million loss in Q1 2025, with cash reserves of $29.7 million expected to fund operations into the first half of 2027.
Key Highlights
- NextCure's SIM0505 received FDA Fast Track designation for platinum-resistant ovarian cancer.
- Initial Phase 1 data for SIM0505 will be presented at ASCO 2026 on June 1, 2026.
- SIM0505 Phase 1 dose optimization study initiated in May 2026 for gynecologic cancers.
- Q1 2026 net loss was $9.8 million, an improvement from $11.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $29.7 million as of March 31, 2026.
- Research and development expenses decreased to $6.8 million in Q1 2026 from $7.9 million in Q1 2025.
- Current financial resources are expected to fund operations into the first half of 2027.